



29 April 2016

## FUNDING UPDATE AND ONGOING SUSPENSION

Optiscan Imaging Limited (ASX:OIL) advises that it has arranged additional debt funding this week totalling \$600,000. This includes a new facility of \$500,000 secured against the 2016 R&D tax incentive claim together with a first charge over the company. A further \$100,000 has been added to the existing secured facility which will now be sub-ordinate to the new debt instrument. Together with additional revenues due shortly, the immediate solvency issue has been addressed.

The Company anticipates making new board appointments shortly and expects to make a further announcement next week in this regard.

The Company is continuing to seek to raise capital and trading of its securities will remain in suspension until the capital raise is completed and the 31 December 2015 Half Year Interim Statements are lodged.

### **About Optiscan**

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Further information:

Peter Delaney, Director of Technology  
Tel (613) 9538 3391  
PeterD@optiscan.com

Bruce Andrew, CFO  
Tel (613) 9538 3398  
brucea@optiscan.com